Skip to main content
. 2022 Aug 17;9(8):ofac419. doi: 10.1093/ofid/ofac419

Figure 1.

Figure 1.

A, Approximate timelines for 3 patients with impaired humoral immunity, clinical evidence of protracted SARS-CoV-2 infection, and nucleocapsid antigenemia during hospitalizations weeks to a month after initial diagnosis. B, Serial blood plasma nucleocapsid measurements during hospitalization for Case 1 and Case 2 show a decline in antigen concentration during antiviral therapy and following treatment with convalescent plasma. Dotted lines represent the approximate duration from first dose to final dose of remdesivir treatment. Available samples for Case 3 demonstrated antigenemia during both the second and third hospitalizations despite receiving 10 days of remdesivir during the second hospitalization. Abbreviations: BAL, bronchoalveolar lavage; CTD-ILD, connective tissue disease–associated interstitial lung disease; NP, Nasopharyngeal; RDV, remdesivir; RT-PCR, reverse transcription polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; VATS, video-assisted thoracoscopic surgery.